Latest News

24 April 2018

What if you could know that your mild cognitive impairment wouldn't progress in the next decade through the result of two simple neuropsychological tests?

Dr. Alves

Researchers from the Lisbon School of Medicine, University of Lisbon found that, in some mild cognitive impairment patients, real neuropsychological stability over a decade is possible and that long-term stability could be predicted based on neuropsychological tests measuring memory and non-verbal abstract reasoning.

23 April 2018

Late, but not too late – Screening for olfactory dysfunction as a marker for cognitive impairment in middle-aged

In a large population-based study of randomly selected participants in Germany, researchers found that participants aged 65-74 years with olfactory dysfunction showed impaired cognitive performance. Interestingly, this strong association was not present in younger (55-64 years) or older (75-86 years) participants. Additionally, the effect was more present in women than men.

22 March 2018

Alzheimer's disease: patients exhibit changes in certain blood lipids that are typical of premature ageing

Medical University Vienna

The neurodegenerative condition known as Alzheimer's disease is the commonest cause of dementia. A research group led by molecular biologists Fabian Dorninger and Johannes Berger at MedUni Vienna's Centre for Brain Research investigated changes in certain lipids (choline phospholipids) in the plasma of elderly people who were healthy and those suffering from Alzheimer's disease.

21 March 2018

JAD celebrates 20th anniversary with open access issue covering 20 years of Alzheimer's research!

The Journal of Alzheimer’s Disease (JAD) celebrates its 20th anniversary during 2018, with the publication of a special anniversary issue (JAD 62:3) in March. This is now available online, with all content open access and freely available to read for all, and features 35 review articles covering 20 years of Alzheimer’s disease (AD) research, plus personal perspectives from researchers in the field.

20 March 2018

Brain SPECT Imaging Predicts Outcomes in Depressed Patients

SPECT image

New research from the Amen Clinics shows that brain SPECT (single photon emission computed tomography) imaging, a study that measures blood flow and activity patterns, identifies who is likely to get better from depression and who is not. The study is published in the Journal of Alzheimer's Disease, because depression is a highly treatable risk for cognitive decline and Alzheimer's disease.

14 March 2018

Exploring the Role of Cognitive Factors in a New Instrument for Elders' Financial Capacity Assessment

Journal of Alzheimer's Disease

Although the general public and mental health professionals seem to disregard incapacity regarding financial issues and relevant decision making in mild cognitive impairment (MCI), and focus only on severe dementia cases, a PhD study in Greece reveals that noticeable deficits do exist in the handling of financial issues in elders suffering from MCI.

12 March 2018

The Role of Verb Fluency in the Detection of Early Cognitive Impairment in Alzheimer's Disease


The ability to generate spoken verbs in infinitive in a given time begins to worsen in the early stages of Alzheimer's disease (AD). Thus, the verb fluency test has been found to be a suitable neuropsychological tool for the detection of healthy aging people at risk of developing cognitive impairment, according to a recent research of the Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, UIC-Barcelona, Spain.

7 March 2018

Fipronil and other pyrazole insecticides induce Amyloid-β42 production

A new study led by Laurent Meijer of ManRos Therapeutics shows that some pyrazole insecticides, of which fipronil is an archetype, trigger enhanced in vitro production of Aβ42/Aβ43 over Aβ40 amyloid peptides in a cell-free, highly purified preparation of γ-secretase, in various cell lines and in neurons differentiated from human-induced pluripotent stem cells (iPSCs) from a healthy or a familial Alzheimer's disease (AD) patient with the APP K724N mutation.


Subscribe to Latest News